Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

ROXANE SEEKING ANDA ROUTE FOR DIAZEPAM AND INDOMETHACIN ORAL SOLUTIONS among five ANDA suitability requests pending for the firm at FDA. The petitions are for major therapeutic products using the company's Intensol concentrated oral solution. Roxane is also petitioning for ANDA suitability of haloperidol, flurazepam and furosemide in Intensol formulations. Roxane already markets several products in its Intensol line. Among these are dihydrotachysterol, dexamethasone, hydrochlorothiazide, morphine sulfate and chlorpromazine hydrochloride. An ANDA is pending for prednisone and the company said in its haloperidol Intensol petition that "many more products [are] under development as a part of Roxane's Intensol product line." The Intensol line was designed "to offer a valuable dosage form alternative for greater compliance; for adults who cannot swallow tablets or capsules; for better accuracy of dosage as compared to the traditional teaspoonful(s); for ease of titration while seeking the effective dose level; and for administration through a nasogastric tube." In addition, Roxane predicted that concern over care for the growing population of elderly may increase demand for its Intensol products. "The need to crush tablets or empty capsules will be obviated by the Intensols," the petitions state. Roxane also notes that "storage of the bottle in a medication cart or on shelves or in drawers is more convenient because of the small size, compared to a pint or larger container as standard for most liquids."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts